期刊
ANNUAL REVIEW OF GENETICS, VOL 54, 2020
卷 54, 期 -, 页码 511-537出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-genet-022820-085940
关键词
Mycobacterium tuberculosis; lineages; principal genetic groups; epigenetics; drug resistance; disease outcome
资金
- Bill and Melinda Gates Research Foundation [OPP1100182]
- South African Medical Research Council
- Department of Health
- Department of Science and Innovation
- South African National Research Foundation [120735]
- Howard Hughes Medical Institute
- European and Developing Countries Clinical Trials Partnership [TMA2018CDF2374]
- Research Foundation Flanders (FWOOdysseus grant) [G0F8316N]
Tuberculosis claims more human lives than any other bacterial infectious disease and represents a clear and present danger to global health as new tools for vaccination, treatment, and interruption of transmission have been slow to emerge. Additionally, tuberculosis presents with notable clinical heterogeneity, which complicates diagnosis, treatment, and the establishment of nonrelapsing cure. How this heterogeneity is driven by the diversity of clinical isolates of the causative agent, Mycobacterium tuberculosis, has recently garnered attention. Herein, we review advances in the understanding of how naturally occurring variation in clinical isolates affects transmissibility, pathogenesis, immune modulation, and drug resistance. We also summarize how specific changes in transcriptional responses can modulate infection or disease outcome, together with strain-specific effects on gene essentiality. Further understanding of how this diversity of M. tuberculosis isolates affects disease and treatment outcomes will enable the development of more effective therapeutic options and vaccines for this dreaded disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据